Results 231 to 236 of about 30,927 (236)

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Lancet Oncology, The, 2014
Jan A Burger, Michael J Keating, William G Wierda   +2 more
exaly  

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

American Journal of Hematology, 2019
Talha Munir, Jennifer R Brown, Susan M O'brien   +2 more
exaly  

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

Nature Communications, 2017
Dan A Landau, Clare Sun, Daniel Rosebrock   +2 more
exaly  

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Journal of Clinical Oncology, 2018
Steven P Treon, Joshua N Gustine, Guang Yang   +2 more
exaly  

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

Lancet Oncology, The, 2016
David A Santos, L Jeffrey Medeiros, Richard E Champlin   +2 more
exaly  

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

New England Journal of Medicine, 2014
John C Byrd, Jennifer R Brown, Susan M O'brien   +2 more
exaly